First AD

Second AD

ASH 2024 Updates: SEQUOIA 5-Year Follow-Up and Expert Perspectives in Selecting Between Acalabrutinib vs Zanubrutinib in TN CLL

Video content above is prompted by the following:

SEQUOIA researchers presented their 5-year follow-up data at this year’s ASH 2024 — could you share key updates from their abstract as well as your impressions? Do these data influence your decision when selecting among the covalent BTKi in treatment-naive CLL? 

How do you decide between acala vs zanu? In which patients would you consider adding obinutuzumab?

Video Series

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

ASH 2024: Updates in the Treatment of CLL  

Peer Exchange

Panelists discuss how long-term SEQUOIA trial data presented at ASH 2024 inform the selection between covalent BTK inhibitors zanubrutinib and acalabrutinib in treatment-naive CLL, including considerations for combining these agents with obinutuzumab.